Detalhe da pesquisa
1.
Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1.
Pancreatology
; 21(1): 192-199, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-33214082
2.
Nanoliposomal irinotecan (Nal-IRI)-based chemotherapy after irinotecan -based chemotherapy in patients with pancreas cancer.
Pancreatology
; 21(2): 379-383, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-33468394
3.
Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer.
Cancer
; 119(24): 4223-30, 2013 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24105075
4.
Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer.
CPT Pharmacometrics Syst Pharmacol
; 10(12): 1550-1563, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34750990
5.
First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study.
Eur J Cancer
; 151: 14-24, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33957442
6.
Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States.
Pancreas
; 49(2): 193-200, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32011529
7.
Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer.
Cancer Chemother Pharmacol
; 71(6): 1499-506, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23543270